Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The phosphatidylinositol-3 kinase (PI3K) pathway is a critical signaling cascade frequently dysregulated in numerous human cancers, including breast, ovarian, and glioblastoma.
• Genetic mutations and overexpression of PI3K are common drivers of tumorigenesis and cancer progression.
• Developing effective PI3K inhibitors is crucial for cancer therapy, yet resistance to current treatments remains a significant challenge.

Purpose of the Study:

• To review the three main classes of phosphatidylinositol-3 kinase (PI3K) inhibitors with demonstrated antitumor activity.
• To discuss structure-activity relationships (SAR) and biological efficacy within each inhibitor class.
• To highlight novel strategies for designing next-generation PI3K inhibitors to overcome acquired resistance.

Main Methods:

• Literature review of preclinical and clinical studies on PI3K inhibitors.
• Classification of PI3K inhibitors into isoform-selective, dual PI3K/m-TOR, and pan-Class I PI3K categories.
• Analysis of structure-activity relationships (SAR) and biological data for each class.

Main Results:

• Detailed examination of isoform-selective PI3K inhibitors (Classes IA, IB, II, III) and their antitumor effects.
• Evaluation of dual pan-Class I PI3K/m-TOR inhibitors and their efficacy.
• Assessment of pan-Class I PI3K inhibitors lacking significant m-TOR activity.
• Discussion of emerging resistance mechanisms and potential therapeutic strategies.

Conclusions:

• The PI3K pathway remains a vital target in oncology, with diverse inhibitor classes showing promise.
• Understanding SAR is key to optimizing inhibitor design for enhanced selectivity and potency.
• Future research should focus on developing novel inhibitors to circumvent resistance and improve patient outcomes in various cancers.